Sanders Targets Florida Drugmaker over Drug’s ‘Staggering’ List Price

Drug Industry Daily
Sen. Bernie Sanders (I-Vt.) took aim at Florida-based drug developer Catalyst Pharmaceutical over what he called the “staggering” list price for Firdapse (amifampridine), a treatment for a rare neuromuscular disease that the company plans to launch in the first quarter of 2019.

To View This Article:


Subscribe To Drug Industry Daily